The Latin America, Middle East and Africa Vaccine Adjuvants Market would witness market growth of 6.0% CAGR during the forecast period (2023-2030).
Widely employed adjuvants, including oil-in-water emulsions and aluminum compounds, are widely acknowledged to elicit more robust antibody responses to vaccine antigens. The capacity of adjuvants to increase total antibody titers and the number of functional antibodies, antibodies with greater affinity for vaccine antigens, or both, is recognized with more attention.
A growing number of vaccines in development are incorporating adjuvants due to the numerous benefits such agents provide, including facilitating the use of lower doses of antigen, enhancing the adaptive response to a vaccine, and directing the type of adaptive response that produces the highest level of immunity for each specific pathogen. Moreover, while most adjuvants utilized in vaccines primarily stimulate humoral immunity, several innovative adjuvants currently undergoing clinical or preclinical research aim to augment particular subtypes of T-cell responses to elicit comprehensive immune reactions necessary for intricate indications like HIV-AIDS and malaria.
The Middle East has grappled with a notable rise in the prevalence of infectious diseases, presenting a complex healthcare challenge across the region. Several factors contribute to this surge. Urbanization, swift population growth, and inadequate sanitation in some areas have created conditions conducive to the spread of infectious pathogens. Rapid urban expansion often leads to overcrowding, compromised hygiene standards, and limited access to clean water, amplifying the risk of disease transmission within communities. Consequently, the increasing incidence of communicable diseases in this region drives the expansion of the market.
The Brazil market dominated the LAMEA Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $29.4 Million by 2030. The Argentina market is showcasing a CAGR of 6.6% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 5.7% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Widely employed adjuvants, including oil-in-water emulsions and aluminum compounds, are widely acknowledged to elicit more robust antibody responses to vaccine antigens. The capacity of adjuvants to increase total antibody titers and the number of functional antibodies, antibodies with greater affinity for vaccine antigens, or both, is recognized with more attention.
A growing number of vaccines in development are incorporating adjuvants due to the numerous benefits such agents provide, including facilitating the use of lower doses of antigen, enhancing the adaptive response to a vaccine, and directing the type of adaptive response that produces the highest level of immunity for each specific pathogen. Moreover, while most adjuvants utilized in vaccines primarily stimulate humoral immunity, several innovative adjuvants currently undergoing clinical or preclinical research aim to augment particular subtypes of T-cell responses to elicit comprehensive immune reactions necessary for intricate indications like HIV-AIDS and malaria.
The Middle East has grappled with a notable rise in the prevalence of infectious diseases, presenting a complex healthcare challenge across the region. Several factors contribute to this surge. Urbanization, swift population growth, and inadequate sanitation in some areas have created conditions conducive to the spread of infectious pathogens. Rapid urban expansion often leads to overcrowding, compromised hygiene standards, and limited access to clean water, amplifying the risk of disease transmission within communities. Consequently, the increasing incidence of communicable diseases in this region drives the expansion of the market.
The Brazil market dominated the LAMEA Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $29.4 Million by 2030. The Argentina market is showcasing a CAGR of 6.6% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 5.7% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Scope of the Study
Market Segments Covered in the Report:
By Type
- Particulate
- Adjuvant Emulsion
- Pathogen
- Combination
- Others
By Administration
- Intramuscular
- Intranasal
- Oral
- Intradermal
- Others
By Application
- Infectious Diseases
- Cancer
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. LAMEA Vaccine Adjuvants Market, by Type
Chapter 6. LAMEA Vaccine Adjuvants Market, by Administration
Chapter 7. LAMEA Vaccine Adjuvants Market, by Application
Chapter 8. LAMEA Vaccine Adjuvants Market, by Country
Chapter 9. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Methodology
LOADING...
